Must be used in combination with other antituberculars
Inhibits DNA-dependent RNA polymerase in susceptible strains of Mycobacterium tuberculosis . Bactericidal for intracellular and extracellular M. tuberculosis organisms.
Use Cautiously in:
The following adverse reactions were reported in patients receiving rifapentine combination therapy and occurred in at least 1% of the patients.
CNS: Headache; dizziness.
DERM: Rash; acne; pruritus; maculopapular rash.
GI: Anorexia; nausea; vomiting; dyspepsia; diarrhea; hemoptysis.
GU: Pyuria; proteinuria; hematuria; urinary casts.
HEMA: Neutropenia; lymphopenia; anemia; leukopenia; thrombocytosis.
HEPA: Increased AST and ALT; hepatitis.
OTHER: Arthralgia; pain; hyperuricemia.
Amitriptyline, amprenavir, azole antifungal agents, barbiturates, buspirone, chloramphenicol, clarithromycin, clofibrate, clozapine, corticosteroids, cyclosporine, dapsone, delavirdine, diazepam, diltiazem, digitalis glycosides, disopyramide, doxycycline, erythromycin, fluconazole, fluoroquinolones, haloperidol, indinavir, itraconazole, ketoconazole, levothyroxine, losartan, methadone, mexiletine, morphine, nelfinavir, nifedipine, nortriptyline, ondansetron, oral contraceptives, phenytoin, progestins, quinidine, quinine, ritonavir, saquinavir, sildenafil, sulfonylureas, tacrolimus, tamoxifen, theophylline, tocainide, toremifene, tricyclic antidepressants, troleandomycin, verapamil, warfarin, zidovudine, zolpidem
Has same interaction potential as rifampin. Potent inducer of hepatic drug metabolizing enzymes. Reduced levels and efficacy of target drugs may occur.
May reduce rifapentine plasma levels, decreasing the therapeutic effects.
Therapeutic Classification: agents for amyotrophic lateral sclerosis, antituberculars
Absorption: 70% absorbed following oral administration.
Distribution: Widely distributed in body tissues and fluids.
Protein Binding: Rifapentine — 97.7%; desacetyl rifapentine — 93.2%.
Metabolism/Excretion: Mostly metabolized by the liver; 17% excreted by the kidneys; some conversion to another active compound (25-desacetyl rifapentine).
Half-life: 13 hr (rifapentine and desacetyl rifapentine).
Copyright ©Nims Drugs2015. All rights reserved.
Powered by : web creation Nepal